-Advertisement-
-Advertisement-
Home
Dexamethasone ophthalmic insert has potential as non-abusable therapy for allergic conjunctivitis
Dry Eye
Dexamethasone ophthalmic insert has potential as non-abusable therapy for allergic conjunctivitis
Due to its sustained 30 day efficacy, intracanalicular dexamethasone insert (Dextenza;) has the potential to be a non-abusable treatment for allergic conjunctivitis, a condition which current standard of care is often linked with steroid abuse, cytotoxic damage, and compliance issues. Data from an analysis of 3 clinical trials evaluating Dextenza...
Read More-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
Contact Info
© 2024 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved